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Abstract
Background Renal dysfunction is a frequent comorbidity
associated with high mortality in patients with chronic
heart failure (CHF). The intrinsic biological age might
affect the ability of the kidney to cope with the challenging
environment caused by CHF. We explored the association
between leukocyte telomere length, a marker for biological
age, and renal function in patients with CHF.
Methods and results Telomere length was determined by
a real-time quantitative polymerase chain reaction in 866
CHF patients. Renal function was estimated with the
simpliﬁed Modiﬁcation of Diet in Renal Disease equation.
The median age was 74 (interquartile range 64–79) years,
61% male, left ventricular ejection fraction of 30 (23–
44)%, and the estimated glomerular ﬁltration rate was 53
(40–68) ml/min/1.73 m
2. Telomere length was associated
with renal function (correlation coefﬁcient 0.123,
P\0.001). This relationship remained signiﬁcant after
adjustment for age, gender, age of CHF onset (standard-
ized-beta 0.091, P = 0.007). Also additionally adjusting
for the severity of CHF and baseline differences did not
change our ﬁndings.
Conclusion The association between shorter leukocyte
telomere length and reduced renal function in heart failure
suggests that intrinsic biological aging affects the ability of
the kidney to cope with the systemic changes evoked by
heart failure.
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Introduction
Chronic heart failure (CHF) is an age-associated disease
with a high prevalence and incidence in Western Society
[8, 24]. Risk factors associated with increased mortality in
patients with CHF include, hypotension, anaemia,
increased BNP levels, activation of the renin-angiotensin
system, and decreased renal function [2, 7, 9, 10, 13, 18,
22, 27]. The precise nature of renal dysfunction in CHF
patients remains to be elucidated. It has been suggested that
the decreased cardiac output, increased inﬂammation and
oxidative stress may challenge the function and integrity of
the kidney in patients with CHF [4, 17]. At some point, a
glomerulus may be irreversibly damaged, leading to
‘‘nephron dropout’’ and accumulating into a progressive
decline of renal function. Recently, we provided pre-
liminary data suggesting a possible association between
shorter telomere length and reduced renal function in a
retrospective study [23]. We hypothesized that a more
advanced intrinsic biological age, reﬂected by telomere
length, increases the susceptibility of the kidney to lose
function in the challenged physiological environment
evoked by CHF.
Telomeres are considered indicators of biological age
and are heritable structures located at the extreme ends of
chromosomes. Telomeres consist of speciﬁc nucleotide
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with several telomere-binding proteins, telomeres protect
chromosomes from recognition and degradation by DNA
damage signalling pathways [6]. When telomeres become
critically short, they lose their protective function and cells
become genetically instable, causing senescence or apop-
tosis [3]. Telomeres are incompletely replicated by DNA
polymerase, causing cumulative attrition of length after
each cell division and marking replicative history [16].
Additional telomere attrition can be caused by damaging
external factors (e.g., oxidative stress, activation of the
renin-angiotensin system) [25, 26]. The aim of our study is
to explore whether systemic leukocyte telomere length is
associated with renal function in patients with CHF.
Methods
This study was a sub-study of the Coordinating Study
Evaluating Outcomes of Advising and Counseling in Heart
Failure (COACH) of which the main ﬁndings have been
published [11, 12]. The COACH-study assessed the value
of additional support by a specialized heart failure nurse in
the treatment of CHF. Eligible patients were aged 18 years
or older, had typical signs and symptoms, and evidence for
structural heart disease conﬁrmed by cardiovascular
imaging. Patients did not necessarily have to have impaired
left ventricular ejection fraction (LVEF). At hospital dis-
charge, patients were stable and on oral heart failure
medication. In total, 157 (15%) of the 1,023 patients who
participated in the COACH were not included in this sub-
study, mainly because of no available DNA (n = 133) or
missing serum creatinine values (n = 18). This study has
been approved by the local Medical Ethics Committee. All
patients gave written informed consent.
Renal function and telomere length
Glomerular ﬁltration rate (GFR) was estimated at
enrollment with the simpliﬁed Modiﬁcation of Diet in
Renal Diseases equation [186.3 9 (serum creatinine/
88.4)
-1.154 9 age
-0.203, in women multiplied by 0.742],
which is one of the most precise and accurate formulas for
calculating GFR [19]. A venous blood sample was taken
from the patients during the ﬁrst outpatient visit and DNA
isolated from it according to standard protocols (Qiagen,
subsidiary Benelux B.V. Venlo, The Netherlands; QIAmp
96 DNA Blood kit, catalog no. 51162). Mean leukocyte
telomere length was measured by quantitative polymerase
chain reaction (PCR) in leukocytes, as previously described
in detail [21]. Telomere length is expressed as T/S ratio,
which is the relative ratio of telomere repeat copy number
‘‘T’’ to a single-gene copy number ‘‘S’’ (36B4). All
samples were assayed in triplicates on separate PCR plates,
but in same well positions. The mean ± SD coefﬁcient of
variation was 7 ± 5% for the T-assay, and 6 ± 4% for S
assay.
Statistical analysis
Telomere length ratio was natural log transformed to obtain
a normal distribution. Baseline characteristics were com-
pared among quartiles of estimated glomerular ﬁltration
rate (eGFR) by one-way analysis of variance, Kruskal–
Wallis test, or Chi-square when appropriate. Pearson cor-
relation coefﬁcient was used to assess the association
between leukocyte telomere length and renal function.
Standard linear regression techniques were used to adjust
for age and gender in a second model and additionally for
age of CHF onset in a third model. This third basic model
was used to subsequently adjust for baseline differences.
Because renal function cannot be assumed to be linearly
related to leukocyte telomere length, it was also modeled as
a fractional polynomial function. A two-sided P value of
\0.05 was considered to indicate statistical signiﬁcance.
All statistical analyses were performed with use of STATA
version 10.0 for Windows software (StataCorp LP, College
Station, TX, USA).
Results
Baseline characteristics according to quartiles of eGFR are
presented in Table 1. The study population consisted of
61% men, median age was 74 years, median LVEF was
30%, with most patients in NYHA class II and III (together
97%). Patients with decreased renal function were less
likely to be men, and more likely to be older of age, to have
higher NYHA class, hypertension, diabetes, atrial ﬁbrilla-
tion or ﬂutter, lower hemoglobin levels, and a previous
admission for CHF (Table 1).
Estimated GFR decreased with age at a yearly rate of
0.70 ± 0.058 ml/min/1.73 m
2 (P\0.001). Telomere
length ratio decreased steadily at a mean rate of
0.0035 ± 0.00064 per year of increase of age (P\0.001).
Telomere length was 0.719 (interquartile range 0.609–
0.881) in the quartile with the highest eGFR, 0.710 (0.604–
0.855) in quartile 2, 0.673 (0.582–0.834) in quartile 3, and
0.667 (0.571–0.825) in the quartile with the lowest eGFR
(P = 0.031). When leukocyte telomere length was mod-
eled as a continuous predictor, renal function decreased
gradually with shorter telomere length. Pearson correlation
coefﬁcient for the association between telomere length and
eGFR was 0.123 (P\0.001). The relationship between
renal function and telomere length remained signiﬁcant
after adjustment for gender and age (standardized-beta
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1230.090; Table 2). In the third basic model we also adjusted
for the age of CHF onset (Fig. 1). Our ﬁndings did not
change after additionally adjusting for baseline differences
(diabetes, hypertension, history of myocardial infarction,
NYHA class, systolic blood pressure, diastolic blood
pressure, heart rate, atrial ﬁbrillation, NT-pro-BNP,
Table 1 Baseline characteristics
Patient characteristics Quartiles of estimated GFR (eGFR) Total, n = 866 P value
1, n = 216 2, n = 217 3, n = 216 4, n = 217
eGFR (ml/min/1.73 m
2) 79 (73–88) 61 (57–65) 46 (43–49) 31 (26–36) 53 (40–68) Deﬁning
criterion
Creatinine (lmol/l) 83 (71–91) 104 (90–113) 131 (113–141) 174 (153–205) 113 (91–144) \0.001
Telomere length
(T/S ratio)
0.72 (0.61–0.88) 0.71 (0.60–0.85) 0.67 (0.58–0.83) 0.67 (0.57–0.82) 0.69 (0.59–0.85) 0.031
Natural log T/S ratio -0.37 ± 0.28 -0.34 ± 0.28 -0.32 ± 0.27 -0.31 ± 0.28 -0.34 ± 0.28 0.031
Age 66 (57–74) 73 (64–79) 75 (67–81) 78 (71–81) 74 (64–79) \0.001
Male gender, n (%) 148 (69) 140 (65) 134 (62) 107 (49) 529 (61) \0.001
NYHA class, n (%)
II 135 (63) 112 (53) 99 (46) 87 (41) 433 (51) 0.001
III 78 (36) 93 (44) 109 (51) 115 (54) 395 (46)
IV 3 (1) 7 (3) 6 (3) 10 (5) 26 (3)
Age of onset CHF (year) 64 (54–73) 71 (62–76) 71 (63–78) 74 (68–79) 71 (61–78) 0.001
LVEF (%) 30 (22–40) 30 (21–44) 30 (23–45) 33 (25–43) 30 (23–44) 0.44
Body mass index
(kg/m
2)
26.0 (23.5–29.4) 26.3 (23.9–29.7) 26.2 (23.7–29.7) 26.1 (23.0–29.4) 26.1 (23.5–29.6) 0.71
Blood pressure (mmHg)
Systolic blood pressure 110 (100–125) 120 (105–130) 115 (105–130) 120 (100–137) 115 (101–130) 0.002
Diastolic blood
pressure
65 (60–76) 70 (60–80) 65 (60–70) 65 (60–75) 69 (60–75) \0.001
Heart rate (beats/min) 76 (66–86) 72 (66–80) 72 (64–80) 72 (64–80) 72 (64–82) 0.03
Medical history, n (%)
Diabetes 52 (24) 52 (24) 60 (28) 81 (37) 245 (28) 0.005
Hypertension 81 (38) 77 (35) 93 (43) 113 (52) 364 (42) 0.002
Myocardial infarction 77 (36) 85 (39) 97 (45) 103 (47) 362 (42) 0.05
Atrial ﬁbrillation/
ﬂutter
76 (44) 91 (42) 107 (50) 110 (51) 384 (44) 0.003
Stroke 18 (8) 17 (8) 26 (12) 26 (12) 87 (10) 0.29
Laboratory measurements
NT-pro-BNP (pg/ml) 2,027 (1,259–
4,242)
1,983 (1,130–
3,624)
3,016 (1,202–
4,742)
4,572 (1,506–
10,664)
2,530 (1,259–
5,548)
\0.001
Hemoglobin (mmol/l) 8.7 (8.0–9.3) 8.8 (7.9–9.3) 8.3 (7.6–9.1) 7.8 (7.1–8.6) 8.4 (7.6–9.2) \0.001
Previous admission,
n (%)
48 (22) 56 (26) 69 (32) 102 (47) 275 (32) \0.001
Current medication, n (%)
RAS-inhibitors 189 (88) 189 (87) 182 (84) 155 (71) 715 (83) \0.001
Beta-blockers 145 (67) 149 (69) 141 (65) 135 (62) 570 (66) 0.52
Diuretics 205 (95) 212 (98) 205 (95) 206 (95) 828 (96) 0.39
Digoxin 77 (36) 63 (29) 74 (34) 52 (24) 266 (31) 0.034
Statins 78 (36) 91 (42) 85 (39) 79 (36) 333 (38) 0.56
Normally distributed data is presented as mean ± SD, skewed distributed data as median (interquartile range). The body-mass index is the
weight in kilograms divided by the square of the height in meters. Diuretics include loop diuretics, thiazides, and aldosterone antagonists
eGFR estimated glomerular ﬁltration rate, NYHA New York Heart Association functional class, CHF chronic heart failure, LVEF left ventricular
ejection fraction, NT-pro-BNP N-terminal pro-B-type natriuretic peptide, RAS-inhibitors renin-angiotensin-system inhibitors (angiotensin-con-
verting enzyme inhibitor and/or angiotensin-receptor blocker)
Clin Res Cardiol (2009) 98:629–634 631
123hemoglobin levels, use of renin-angiotensin system inhib-
itors, and digoxin; Table 2).
Discussion
A frequent co-morbidity factor and powerful predictor of
mortality in CHF is decreased renal function [7, 10, 13].
The main ﬁnding of this study is that reduced leukocyte
telomere length, as a marker for advanced intrinsic bio-
logical age, is associated with decreased renal function in
patients with CHF. This observation remained signiﬁcant
after adjustment for several confounders, including age,
age of CHF onset, and severity of CHF.
Telomere length is associated with CHF. We recently
demonstrated telomere length to be shorter in 620 patients
with CHF compared to healthy controls [21]. This was also
observed by others [15]. In addition, levels of TRF2—one
of the telomere-stabilizing proteins—in the myocardium of
heart failure patients was found to be down-regulated by
approximately 50% compared to healthy controls [15].
Interestingly, Werner et al. found that physical exercise in
mice up-regulated TRF2, and protected the myocardium
from doxorubicin-induced apoptosis [28]. Thus, telomere
biology is not only associated with CHF, but seems to be a
modiﬁable factor in heart failure. Possibly, telomeres are a
new therapeutic target in heart failure.
A retrospective analysis of the cohort of 620 CHF
patients suggested a potential association between telo-
mere length and renal function [23]. Obviously, retro-
spective analysis is susceptible to type-1 errors. The
current prospective study, however, provides important
independent conﬁrmation of these preliminary ﬁndings.
Reduced renal function might be associated with shorter
telomere length in patients with CHF for several reasons.
First, the processes biological aging and renal senescence
associated with renal function decline includes a
decreased ability of aged nephrons to cope with diseased
states. CHF elicits systemic changes, including decreased
cardiac output, inﬂammation, oxidative stress, and acti-
vation of the renin-angiotensin system [4, 22]. Nephrons
with shorter telomeres might be less resistant to these
challenges and more likely to enter a senescence state,
become dysfunctional or even apoptotic. The phenotype
of human renal senescence has indeed been described
Table 2 Univariate and
adjusted standardized beta for
association between renal
function and telomere length
Model 1: univariate; Model 2:
adjusted for age and gender;
Model 3; adjusted for age, age
of heart failure onset, and
gender
NYHA New York Heart
Association functional class,
NT-pro-BNP N-terminal pro-B-
type natriuretic peptide, RAS-
inhibitors renin-angiotensin-
system inhibitors (angiotensin-
converting enzyme and/or
angiotensin-receptor blocker)
Standardized-beta 95%CI P value
Model 1 0.123 0.057–0.189 \0.001
Model 2 0.090 0.023–0.157 0.008
Model 3 0.091 0.024–0.158 0.007
Model 3
? Diabetes 0.090 0.023–0.157 0.008
? Hypertension 0.091 0.024–0.159 0.008
? Previous myocardial infarction 0.092 0.024–0.158 0.007
? NYHA class 0.085 0.018–0.153 0.013
? Systolic blood pressure 0.088 0.021–0.155 0.010
? Diastolic blood pressure 0.090 0.023–0.157 0.009
? Heart rate 0.090 0.023–0.157 0.009
? Atrial ﬁbrillation/ﬂutter 0.091 0.024–0.157 0.008
? NT-pro-BNP 0.103 0.011–0.194 0.028
? Hemoglobin 0.100 0.010–0.187 0.029
? RAS-inhibitors 0.074 0.007–0.142 0.031
? Digoxin 0.094 0.027–0.161 0.006
Fig. 1 Renal function histogram and association with telomere
length. Bars represent the histogram of renal function (left Y-axis;
percentage of subjects per bar). Black line represents the squared
relationship between renal function and telomere length after
adjustment for age, age of heart failure onset, and gender. The
shaded area indicate the 95% conﬁdence limits as estimated by the
fractional polynomial function
632 Clin Res Cardiol (2009) 98:629–634
123previously as the loss of mass and function, including a
loss of GFR [14]. Second, leukocytes telomeres mark
replicative history and therefore might mark the cumula-
tive inﬂammatory burden a patient has been exposed to
[1]. Inﬂammation is a major causal factor of vasculo- and
glomerulopathy and consequently might cause a decrease
in renal function. Finally, other factors associated with
biological aging (e.g., accumulation of advanced glyca-
tion endproducts) might cause renal dysfunction and
coincide with shorter telomere length [20].
The cross-sectional nature of our study does not allow
drawing deﬁnite conclusions concerning the nature of the
observed association. Although we used multiple statistical
adjustments, we cannot exclude possible confounding
factors that may have obscured the observed relationship.
In conclusion, decreased renal function was associated
with reduced leukocyte telomere length in patients with
CHF. This observation support the hypothesis that
increased intrinsic biological age affects the kidney in its
ability to cope with the systemic changes evoked by CHF
and might explain, at least in part, why renal function is
closely related to mortality in patients with CHF.
Acknowledgments We like to thank all the patients, investigators,
heart failure nurses, and the committees of the COACH-study (for
names see Ref. [11]). We are indebted to Germaine Benus for her
excellent technical support. The COACH-study was supported by
NetherlandsHeartFoundation(Grant2000Z003).Telomereresearchis
supported by the Innovational Research Incentives Scheme program of
the Netherlands Organisation for Scientiﬁc Research (NWO VENI,
grant 916.76.170 to P. van der Harst), the Interuniversitair Cardiolo-
gisch Instituut Nederland (ICIN), and the Netherlands Heart Founda-
tion (grant 2006B140). L.S.M. Wong, P. van der Harst and R.A. de
Boer are research fellows of the Netherlands Heart Foundation (grant
2008T028,2006T003,and2004T004,respectively).N.J.Samaniholds
a British Heart Foundation Chair. D.J. van Veldhuisen and A.A. Voors
are Established Investigators of the Netherlands Heart Foundation
(grant D97-017 and 2006T037 respectively). None of the funders had
a role in the study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Aviv A (2006) Telomeres and human somatic ﬁtness. J Gerontol
A Biol Sci Med Sci 61:871–873
2. Best PJ, Holmes DR Jr (2003) Chronic kidney disease as a car-
diovascular risk factor. Am Heart J 145:383–386
3. Blasco MA (2005) Telomeres and human disease: ageing, cancer
and beyond. Nat Rev Genet 6:611–622
4. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B
(2005) The severe cardiorenal syndrome: ‘Guyton revisited’. Eur
Heart J 26:11–17
5. Brouilette SW, Whittaker A, Stevens SE, van der Harst P, Goo-
dall AH, Samani NJ (2008) Telomere length is shorter in healthy
offspring of subjects with coronary artery disease: support for the
telomere hypothesis. Heart 94:422–425
6. Chan SR, Blackburn EH (2004) Telomeres and telomerase.
Philos Trans R Soc Lond B Biol Sci 359:109–121
7. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD,
Cleland JG, van Veldhuisen DJ, Hillege HL (2007) Worsening
renal function and prognosis in heart failure: systematic review
and meta-analysis. J Card Fail 13:599–608
8. Gillum RF (1993) Epidemiology of heart failure in the United
States. Am Heart J 126:1042–1047
9. Gorelik O, Almoznino-Saraﬁan D, Shteinshnaider M, Alon I,
Tzur I, Sokolsky I, Efrati S, Babakin Z, Modai D, Cohen N
(2009) Clinical variables affecting survival in patients with
decompensated diastolic versus systolic heart failure. Clin Res
Cardiol 98:224–232
10. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ,
Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de
Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as
a predictor of outcome in a broad spectrum of patients with heart
failure. Circulation 113:671–678
11. Jaarsma T, van der Wal MH, Hogenhuis J, Lesman I, Luttik ML,
Veeger NJ, van Veldhuisen DJ (2004) Design and methodology
of the COACH study: a multicenter randomised Coordinating
Study Evaluating Outcomes of Advising and Counselling in
Heart failure. Eur J Heart Fail 6:227–233
12. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML,
Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst
WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van
Veldhuisen DJ (2008) Effect of moderate or intensive disease
management program on outcome in patients with heart failure:
Coordinating Study Evaluating Outcomes of Advising and
Counseling in Heart Failure (COACH). Arch Intern Med
168:316–324
13. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004)
Renal insufﬁciency and heart failure: prognostic and therapeutic
implications from a prospective cohort study. Circulation
109:1004–1009
14. Melk A (2003) Senescence of renal cells: molecular basis and
clinical implications. Nephrol Dial Transplant 18:2474–2478
15. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE,
Michael LH, Youker KA, Entman ML, Schneider MD (2003)
Telomere attrition and Chk2 activation in human heart failure.
Proc Natl Acad Sci USA 100:5378–5383
16. Samani NJ, van der Harst P (2008) Biological ageing and car-
diovascular disease. Heart 94:537–539
17. Smilde TD, Damman K, van der Harst P, Navis G, Daan We-
stenbrink B, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege
HL (2009) Differential associations between renal function and
‘‘modiﬁable’’ risk factors in patients with chronic heart failure.
Clin Res Cardiol 98:121–129
18. Smilde TD, Hillege HL, Navis G, Boomsma F, de Zeeuw D,
van Veldhuisen DJ (2004) Impaired renal function in patients
with ischemic and nonischemic chronic heart failure: association
with neurohormonal activation and survival. Am Heart J
148:165–172
19. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL
(2006) Drawbacks and prognostic value of formulas estimating
renal function in patients with chronic heart failure and systolic
dysfunction. Circulation 114:1572–1580
20. Smit AJ, Hartog JW, Voors AA, van Veldhuisen DJ (2008)
Advanced glycation endproducts in chronic heart failure. Ann
NY Acad Sci 1126:225–230
21. van der Harst P, van der Steege G, de Boer RA, Voors AA, Hall
AS, Mulder MJ, van Gilst WH, van Veldhuisen DJ (2007)
Clin Res Cardiol (2009) 98:629–634 633
123Telomere length of circulating leukocytes is decreased in patients
with chronic heart failure. J Am Coll Cardiol 49:1459–1464
22. van der Harst P, Volbeda M, Voors AA, Buikema H, Wassmann
S, Bohm M, Nickenig G, van Gilst WH (2004) Vascular
response to angiotensin II predicts long-term prognosis in patients
undergoing coronary artery bypass grafting. Hypertension
44:930–934
23. van der Harst P, Wong LS, de Boer RA, Brouilette SW, van der
SG, Voors AA, Hall AS, Samani NJ, Wikstrand J, van Gilst WH,
van Veldhuisen DJ (2008) Possible association between telomere
length and renal dysfunction in patients with chronic heart failure.
Am J Cardiol 102:207–210
24. van Jaarsveld CH, Ranchor AV, Kempen GI, Coyne JC, van
Veldhuisen DJ, Sanderman R (2006) Epidemiology of heart
failure in a community-based study of subjects aged [ or = 57
years: incidence and long-term survival. Eur J Heart Fail 8:23–30
25. Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White
C, Wang TJ, Gardner JP, Cao X, Benjamin EJ, Levy D, Aviv A
(2008) Association of leukocyte telomere length with circulating
biomarkers of the renin-angiotensin-aldosterone system. The
Framingham Heart Study. Circulation 117:1138–1144
26. von Zglinicki T (2002) Oxidative stress shortens telomeres.
Trends Biochem Sci 27:339–344
27. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, Unger
T, Yusuf S, Bohm M (2008) RAS blockade with ARB and ACE
inhibitors: current perspective on rationale and patient selection.
Clin Res Cardiol 97:418–431
28. Werner C, Hanhoun M, Widmann T, Kazakov A, Semenov A,
Poss J, Bauersachs J, Thum T, Pfreundschuh M, Muller P,
Haendeler J, Bohm M, Laufs U (2008) Effects of physical
exercise on myocardial telomere-regulating proteins, survival
pathways, and apoptosis. J Am Coll Cardiol 52:470–482
634 Clin Res Cardiol (2009) 98:629–634
123